Your browser doesn't support javascript.
loading
Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study.
Cocito, Dario; Peci, Erdita; Romagnolo, Alberto; Rigaldo, Simona; Rosso, Michela; Lopiano, Leonardo; Merola, Aristide.
Afiliación
  • Cocito D; Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Torino, Italy. Electronic address: dario.cocito@unito.it.
  • Peci E; Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Torino, Italy.
  • Romagnolo A; Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Torino, Italy.
  • Rigaldo S; Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Torino, Italy.
  • Rosso M; Department of Neurology, University of Cincinnati Gardner Neuroscience Institute, 260 Stetson St, Suite 2300, Cincinnati, OH 267-0525, USA.
  • Lopiano L; Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Torino, Italy.
  • Merola A; Department of Neurology, University of Cincinnati Gardner Neuroscience Institute, 260 Stetson St, Suite 2300, Cincinnati, OH 267-0525, USA.
J Neurol Sci ; 380: 54-57, 2017 Sep 15.
Article en En | MEDLINE | ID: mdl-28870589
BACKGROUND: Subcutaneous (SC) immunoglobulin (Ig) is an effective therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). However, optimal dosage and frequency of administration remain to be clarified. OBJECTIVES: We sought to assess the feasibility and tolerability of a novel regimen of SCIg administration, based on concentrated "bolus" doses delivered every other week, as compared to the "conventional" SCIg regimen, based on 1-3 administrations/week. MATERIALS AND METHODS: Consecutively consenting CIDP patients (6 men and 1 woman) were crossed-over from SCIg "conventional" to SCIg "bolus" and followed-up for 6months. The main endpoints were: tolerability, defined as the percentage of patients successfully completing the study, patient's perceived disability, as measured by the Rasch-built Overall Disability Scale (R-ODS), life quality index (LQI), and inflammatory neuropathy cause and treatment (INCAT) scale. RESULTS: SCIg "bolus" was well tolerated by all patients. The R-ODS score significantly improved (p=0.042), as well as the LQI sub-domains related to the interference of treatment in daily living activities (p=0.026), and therapy-related problems (p=0.039). No significant change was observed in the INCAT (p=0.317) score. There were no cases of drop-out and/or dose adjustment during follow-up. CONCLUSIONS: SCIg "bolus" seems to represent an effective and well-tolerated option for CIDP maintenance therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas / Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Sci Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoglobulinas / Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante / Factores Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Sci Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos